blockonomi.comNov 9$IBRX

ImmunityBio (IBRX) Stock Falls 18% Despite Cancer Trial Win and 92% Sales Growth

ImmunityBio (IBRX) reported Q3 revenue of $48.7M, up 53%, and nine-month revenue of $143.6M, up 92%. The company's ANKTIVA plus BCG met primary trial goals, but shares fell 18% on rising costs and losses. IBRX plans a supplemental BLA for BCG-naive patients in Q4 2026.

Original reporting

blockonomi.com

Published Nov 9, 2026, 2:40 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 9, 2026, 3:08 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

ImmunityBio (IBRX) Stock Falls 18% Despite Cancer Trial Win and 92% Sales Growth — source image — Source · blockonomi.com

Decision brief

The 30-second read

$IBRXBearishLow

Why it matters

The market reaction suggests investors are discounting the trial win, possibly due to broader profit‑loss concerns.

Market read

Provides fresh earnings and clinical data for a mid‑cap biotech, highlighting a disconnect between fundamentals and price action.

What to watch

Potential upcoming BLA filing and expanding international approvals may support longer‑term upside.

Relevance 7/10Novelty 7/10Timing: today

Background

ImmunityBio reported Q3 financials and a positive bladder cancer trial result, but the stock fell sharply.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$IBRXBearishHigh confidence

Context

Q3 earnings released with 53% revenue growth and a positive bladder cancer trial result, yet the stock fell 18% on the same day.

Expected impact

downward pressure as investors sell despite positive trial news and revenue growth

Evidence & confidence

Price already dropped 18% on news day; lack of clear catalyst for upside implies continued downside risk.

Market effects

Sector

Biotech sector may see heightened scrutiny of trial data versus stock reactions.

Regional

US biotech investors may reassess risk on trial announcements.

Global

Limited to ImmunityBio and similar oncology developers.

Counterpoint

What could challenge this read

The trial win could be a catalyst for a rebound if the sell‑off is over‑reaction.

Key entities

company
ImmunityBio, Inc.
Biotech firm developing immunotherapy for bladder cancer.

Read at source ← All news

$IBRXMed

Why ImmunityBio Stock Dropped 15% After Earnings Despite 53% Sales Growth. Is IBRX Now a Buy?

ImmunityBio (IBRX) reported 53% sales growth for ANKTIVA, its bladder-cancer immunotherapy, to $48.7M in Q3, but missed estimates and saw stock drop 15%. The company faces cash flow challenges and relies on FDA approval for expanded ANKTIVA use. IBRX trades at 39x sales with $334.3M in cash, enough for ~4 quarters at current burn rate.

finance.yahoo.comNov 9

$IBRXHigh

ImmunityBio shares slump 19% as revenue misses and going-concern warning hits sentiment

ImmunityBio (NASDAQ:IBRX) shares dropped 19% to $6.97 after reporting Q3 revenue of $48.84M, below expectations of $59.25M. Net loss widened to $184.6M, with a going-concern warning. Cash reserves are $334.3M, but $217.2M was used in 9 months. ANKTIVA, its bladder cancer treatment, showed positive trial results and regulatory approvals.

finance.yahoo.comNov 9

HighAI 8/10

ImmunityBio Stock Sinks 20% as Revenue Misses Estimates Despite Bladder Cancer Trial Win and Israel Approval

ImmunityBio Inc. shares fell 20% after Q3 revenue of $48.84M missed estimates of $59.23M, despite a successful bladder cancer trial and Israel approval. The company reported a loss of 9 cents per share, wider than expected. Revenue grew 53% year-over-year but declined from the prior quarter. Anktiva, its lead product, saw expanded approvals and positive trial results.

ibtimes.com.auNov 9

$IBRXHigh

Immunitybio Inc earnings missed by $0.10, revenue fell short of estimates

Immunitybio Inc (IBRX) reported Q3 EPS of -$0.18, missing estimates by $0.10, and revenue of $48.84M, below the $59.23M consensus. The stock is up 12.94% in 3 months and 206.48% in 12 months. InvestingPro rates its financial health as 'good performance'.

investing.comNov 9

$IBRXHighAI 8/10

ImmunityBio 3Q 2026: Revenue $48.84M, EPS ($0.18) — 10-Q Summary

ImmunityBio reported 3Q 2026 revenue of $48.84M, up 52% YoY, driven by ANKTIVA sales. Net loss widened to $50.45M due to higher R&D and SG&A costs. FDA approved ANKTIVA for additional use. IBRX

tradingview.comNov 9

Med

ImmunityBio Q3 2026: A $77.9M Charge Masks Real ANKTIVA Progress

ImmunityBio reported Q3 2026 revenue of $48.84M, up 52% YoY but below estimates. A $77.9M non-cash charge drove a larger-than-expected loss. ANKTIVA, its bladder cancer immunotherapy, generated $48.74M in revenue, up 53% YoY. The FDA approved a label expansion. Cash reserves decreased 25% YoY to $45.08M.

247wallst.comNov 9